Company
Resilience Biosciences (Resilience)
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 1 min read
What it is
National Resilience (often just "Resilience") is a US biomanufacturing company building manufacturing infrastructure for cell therapies, gene therapies, viral vectors, mRNA, plasmid DNA, and other modalities. Not a drug-developer itself but enables many of the longevity-relevant biotechs.
Why infrastructure matters for longevity
Most leading longevity biotechs work on modalities that require complex biomanufacturing:
- Gene therapies (Rejuvenate Bio, Life Biosciences) need AAV vectors.
- Cell therapies need GMP cell-culture facilities.
- mRNA platforms (Turn Biotechnologies) need LNP and mRNA synthesis at scale.
- Cellular reprogramming programmes need specialised cell handling.
Resilience and similar CDMOs (Catalent, Lonza, Charles River) make these programmes possible without each company building its own factory.
Why it’s here
Often overlooked in popular longevity-company lists, biomanufacturing infrastructure is rate-limiting for the field. Without it, most gene-therapy and cell-therapy programmes can’t scale beyond academic proof-of-concept.